Furthermore, there was no obvious risk associated with these more ambitious titration targets, since the proportion of patients reporting any symptomatic or even severe hypoglycemia and the weight gain observed with initiating basal insulin therapy were not higher aiming for lower fasting plasma glucose titration targets. The gene discussed is INS; the disease is Hypoglycemia.